Pinterest • The world’s catalogue of ideas

Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primary mechanism is direct stimulation of β1 receptors of the sympathetic nervous system. Dobutamine is used to treat acute but potentially reversible heart failure, such as which occurs during cardiac surgery or in cases of septic or cardiogenic shock, on the basis of its positive inotropic action. Dobutamine can be used in cases of congestive heart failure to increase cardiac output.

Table 4. Diuretics used in the treatment of heart failure.

New Drug May Transform Treatment of Heart Failure

A new drug is showing significant promise in improving the treatment of heart failure, after a clinical trial showed it lowered the chances of death or hospital

New Drug May Transform Treatment of Heart Failure

A new drug is showing significant promise in improving the treatment of heart failure, after a clinical trial showed it lowered the chances of death or hospitalization by about 20 percent compared to the current standard drug treatment.Researchers recently released clinical trial results for the drug, called LCZ696. The data from the clinical trial was so compelling that an ethics council monitoring the trial data requested that the study end seven months early.Results were showing that

Table 5. Treatment of heart failure with diuretics (loop diuretics, thiazides, metolazone).

General Information about Heart Failure--- If you follow the website, the American Heart Association has provided a multitude of links and information that answers the basics like what heart failure is, warning signs, understanding your risk, as well as ways to prevent heart failure from happening to you. It also provides tools and resources to assist individuals dealing with heart failure as well as providing support for caregivers as well.

4
1

Heart's own stem cells offer hope for new treatment of heart failure

Last year, Kings College London announced that for the first time they had been able to highlight the regenerative capabilities of stem cells which live in the heart. Clinical trials are due to take place later this year.